Brief: Ascletis Announces Positive Data Of Oral Double Prodrug Asc10 And Its Antiviral Nucleoside Analog Asc10-A Against Omicron Variant
07/02/2022 11:16
Feb 7 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES POSITIVE DATA OF ORAL DOUBLE PRODRUG
ASC10
AND ITS ANTIVIRAL NUCLEOSIDE ANALOG ASC10-A AGAINST OMICRON
VARIANT
* ASCLETIS PHARMA INC - ASC10-A DEMONSTRATED STRONG IN VITRO
ANTIVIRAL ACTIVITY AGAINST MULTIPLE SARS-COV-2 VIRUS VARIANTS
INCLUDING OMICRON
Source text for Eikon: ID:nPn2C4Vfga
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026